The Global Oral GLP-1 Market was valued at approximately USD 5.01 Billion in 2024 and reached USD 6.20 Billion in 2025. The market is projected to grow to USD 42.50 Billion by 2034, expanding at a CAGR of 23.8% during the forecast period from 2026 to 2034. This rapid expansion is primarily fueled by the "Oral Transition" of 2026, as the pharmaceutical industry successfully shifts from weekly injections to high-bioavailability "small molecule" pills like Eli Lilly’s Foundayo and other non-peptide agonists that eliminate strict fasting requirements. Furthermore, the 2026 policy shift in the U.S.—specifically the implementation of the BALANCE pilot program—is making these therapies accessible to millions of Medicare and Medicaid recipients with a $50 monthly out-of-pocket cap, effectively moving oral GLP-1s from a premium lifestyle choice to a standard-of-care foundation for the global management of obesity, heart failure, and chronic kidney disease.

The Global Peptide Therapeutics Market was valued at approximately USD 54.84 Billion in 2024 and reached USD 58.40 Billion in 2025. The market is projected to grow to USD 102.70 Billion by 2034, expanding at a CAGR of 6.5% during the forecast period from 2026 to 2034. This steady rise in valuation is mainly due to the "GLP-1 Renaissance" of 2026. Next-generation multi-receptor agonists, which target GLP-1, GIP, and Glucagon, are expanding beyond obesity and into chronic kidney disease and MASH (metabolic dysfunction-associated steatohepatitis) conditions. Additionally, the 2026 breakthrough in "Oral Peptide Scaffolding" is overcoming traditional bioavailability issues. This advancement allows blockbuster injectables to transition into high-compliance oral formats. These new formats are expected to capture up to 23% of the metabolic market share by the end of the decade.

The Global Small Interfering RNA (siRNA) Therapeutics Market was valued at approximately USD 3.28 Billion in 2024 and reached USD 3.80 Billion in 2025. The market is projected to grow to USD 14.20 Billion by 2034, expanding at a CAGR of 15.8% during the forecast period from 2026 to 2034. This accelerated growth is primarily driven by the "Subcutaneous Revolution" of 2026, where the refinement of GalNAc-conjugation has established a new standard for patient-friendly, liver-targeted administration that bypasses the need for hospital-based infusions. Furthermore, the 2026 surge in "Biotech-Hyperscaler" partnerships is leveraging generative AI to predict RNA-protein interactions with 90% accuracy, cutting drug discovery timelines for complex oncological and neurodegenerative targets by nearly half and fueling a record-breaking pipeline of over 50 siRNA candidates in active clinical trials.

The Global Oligonucleotide Therapeutics Market was valued at approximately USD 7.25 Billion in 2024 and reached USD 8.20 Billion in 2025. The market is projected to grow to USD 24.80 Billion by 2034, expanding at a CAGR of 13.1% during the forecast period from 2026 to 2034. This robust growth is primarily driven by the "RNA Revolution," where advancements in delivery chemistries like GalNAc-conjugation and lipid nanoparticles have finally unlocked the ability to target tissues beyond the liver, such as the central nervous system and heart. Furthermore, the 2026 industry pivot toward "Precision RNA Editing" is allowing companies to move from simply silencing genes to actively repairing them, creating a massive new pipeline for chronic conditions like cardiovascular disease and high-volume oncological indications that were previously considered undruggable.

The Global Antisense Oligonucleotide Market was valued at approximately USD 4.10 Billion in 2024 and reached USD 4.60 Billion in 2025. The market is projected to grow to USD 12.80 Billion by 2034, expanding at a CAGR of 12.1% during the forecast period from 2026 to 2034. This robust growth is primarily fueled by the "Precision Medicine Pivot" of 2026, where advancements in GalNAc-conjugation and lipid nanoparticle delivery have successfully expanded the reach of antisense therapies beyond liver-hosted diseases to include the central nervous system and lung tissue. Furthermore, the 2026 integration of AI-driven sequence design is drastically reducing off-target toxicities, allowing for a surge in "N-of-1" personalized treatments for ultra-rare genetic disorders and propelling the technology into mainstream use for large-population chronic conditions like cardiovascular disease and high cholesterol.

The Global Neoantigen Vaccine Market was valued at approximately USD 2.45 Billion in 2024 and reached USD 2.8 Billion in 2025. The market is projected to grow to USD 9.4 Billion by 2034, expanding at a CAGR of 14.4% during the forecast period from 2026 to 2034. This robust growth is driven by a paradigm shift toward personalized oncology, where advanced Next-Generation Sequencing (NGS) and AI-driven bioinformatics allow for the rapid identification of patient-specific tumor mutations. Furthermore, the success of mRNA and peptide-based platforms in clinical trials has shortened vaccine manufacturing timelines, making these bespoke immunotherapies a viable frontline treatment alongside traditional checkpoint inhibitors.

The Global Amniotic Membrane Market is estimated at USD 4.4 Billion in 2024 and is on track to reach roughly USD 14.3 Billion by 2034, The market is further estimated to reach approximately USD 4.9 Billion in 2025, and is expected to expand at a compound annual growth rate (CAGR) of around 12.5% during the forecast period from 2026 to 2034. Growth is driven by increasing adoption of regenerative medicine, rising demand for advanced wound care solutions, and expanding applications in ophthalmology, orthopedics, and surgical procedures. Additionally, advancements in tissue preservation technologies and growing awareness of biologics-based therapies are further supporting market expansion globally.

The Global Multiple Unit Pellet Systems Market is estimated at US$ 3.7 Billion in 2024 and is on track to reach roughly US$ 5.1 Billion by 2034, The market is further estimated to reach approximately US$ 3.8 Billion in 2025, and is expected to expand at a compound annual growth rate (CAGR) of around 3.3% during the forecast period from 2026 to 2034. Growth is driven by increasing demand for controlled-release drug delivery systems, rising adoption of multi-unit pellet technologies in pharmaceutical formulations, and growing focus on patient-centric dosage forms. Additionally, advancements in pellet coating technologies and expansion of generic drug manufacturing are further supporting market growth globally.

The Global Radiopharmaceutical Market was valued at approximately USD 10.8 Billion in 2024 and increased to USD 11.9 Billion in 2025. The market is projected to reach nearly USD 27.6 Billion by 2034, expanding at a compound annual growth rate (CAGR) of 9.8% during the forecast period from 2026 to 2034. Market growth is primarily driven by the increasing prevalence of cancer and cardiovascular diseases, rising adoption of nuclear medicine for diagnostic and therapeutic applications, and growing demand for targeted radiotherapy. Additionally, advancements in imaging technologies, expanding pipeline of novel radiopharmaceuticals, and increasing investments in healthcare infrastructure are expected to further accelerate market expansion globally.

The Global mRNA Vaccine and Therapeutics Market was valued at approximately USD 6.2 Billion in 2024 and increased to USD 6.9 Billion in 2025. The market is projected to reach nearly USD 21.2 Billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.3% during the forecast period from 2026 to 2034. Market growth is primarily driven by the continued commercialization of mRNA-based vaccines alongside rapid expansion into oncology, rare disease, and personalized medicine applications. Additionally, increasing regulatory approvals, advancements in delivery technologies such as lipid nanoparticles, and strong pipeline development across therapeutic areas are expected to further accelerate adoption and long-term market expansion.

The Global Lipid Nanoparticle Drug Delivery Market was valued at approximately USD 7.6 Billion in 2024 and increased to USD 8.4 Billion in 2025. The market is projected to reach nearly USD 24.6 Billion by 2034, expanding at a compound annual growth rate (CAGR) of 12.7% during the forecast period from 2026 to 2034. Market growth is primarily driven by the increasing adoption of lipid nanoparticle platforms for mRNA vaccines, gene therapies, and targeted drug delivery applications. Additionally, rising investments in nanomedicine research, expanding clinical pipelines for RNA-based therapeutics, and technological advancements in lipid formulation and delivery systems are expected to further accelerate the adoption of lipid nanoparticle drug delivery technologies across pharmaceutical and biotechnology sectors.

The Spain Enteric Softgel Capsules Market was valued at USD 0.158 B in 2024 and is projected to reach approximately USD 0.185 B in 2025. The market is further expected to expand to nearly USD 0.290 B by 2034, registering a compound annual growth rate (CAGR) of about 7.4% during the forecast period from 2026 to 2034. Growth in the market is driven by the increasing demand for targeted drug delivery systems and improved oral dosage formulations in the pharmaceutical and nutraceutical industries. Enteric softgel capsules help protect active ingredients from stomach acid and ensure release in the intestine, improving drug stability, absorption efficiency, and patient compliance.

The Italy Enteric Softgel Capsules Market was valued at USD 0.234 B in 2024 and is projected to reach approximately USD 0.278 B in 2025. The market is further expected to expand to nearly USD 0.351 B by 2034, registering a compound annual growth rate (CAGR) of about 6.4% during the forecast period from 2026 to 2034. Growth in the market is driven by the increasing demand for targeted drug delivery systems and improved oral dosage formulations in the pharmaceutical and nutraceutical industries. Enteric softgel capsules help protect active ingredients from stomach acid and ensure release in the intestine, improving drug stability, absorption efficiency, and patient compliance.

The France Enteric Softgel Capsules Market was valued at USD 0.230 B in 2024 and is projected to reach approximately USD 0.335 B in 2025. The market is further expected to expand to nearly USD 0.490 B by 2034, registering a compound annual growth rate (CAGR) of about 5.9% during the forecast period from 2026 to 2034. Growth in the market is driven by the increasing demand for targeted drug delivery systems and improved oral dosage formulations in the pharmaceutical and nutraceutical industries. Enteric softgel capsules help protect active ingredients from stomach acid and ensure release in the intestine, improving drug stability, absorption efficiency, and patient compliance.

The Germany Enteric Softgel Capsules Market was valued at USD 0.316 B in 2024 and is projected to reach approximately USD 0.405 B in 2025. The market is further expected to expand to nearly USD 0.622 B by 2034, registering a compound annual growth rate (CAGR) of about 8.1% during the forecast period from 2026 to 2034. Growth in the market is driven by the increasing demand for targeted drug delivery systems and improved oral dosage formulations in the pharmaceutical and nutraceutical industries. Enteric softgel capsules help protect active ingredients from stomach acid and ensure release in the intestine, improving drug stability, absorption efficiency, and patient compliance.

The UK Enteric Softgel Capsules Market was valued at USD 0.268 B in 2024 and is projected to reach approximately USD 0.322 B in 2025. The market is further expected to expand to nearly USD 0.535 B by 2034, registering a compound annual growth rate (CAGR) of about 8.3% during the forecast period from 2026 to 2034. Growth in the market is driven by the increasing demand for targeted drug delivery systems and improved oral dosage formulations in the pharmaceutical and nutraceutical industries. Enteric softgel capsules help protect active ingredients from stomach acid and ensure release in the intestine, improving drug stability, absorption efficiency, and patient compliance.

The Chile Enteric Softgel Capsules Market was valued at USD 0.146 B in 2024 and is projected to reach approximately USD 0.167 B in 2025. The market is further expected to expand to nearly USD 0.230 B by 2034, registering a compound annual growth rate (CAGR) of about 4.1% during the forecast period from 2026 to 2034. Growth in the market is driven by the increasing demand for targeted drug delivery systems and improved oral dosage formulations in the pharmaceutical and nutraceutical industries. Enteric softgel capsules help protect active ingredients from stomach acid and ensure release in the intestine, improving drug stability, absorption efficiency, and patient compliance.

The Mexico Enteric Softgel Capsules Market was valued at USD 0.390 B in 2024 and is projected to reach approximately USD 0.450 B in 2025. The market is further expected to expand to nearly USD 0.710 B by 2034, registering a compound annual growth rate (CAGR) of about 6.1% during the forecast period from 2026 to 2034. Growth in the market is driven by the increasing demand for targeted drug delivery systems and improved oral dosage formulations in the pharmaceutical and nutraceutical industries. Enteric softgel capsules help protect active ingredients from stomach acid and ensure release in the intestine, improving drug stability, absorption efficiency, and patient compliance.

The Brazil Enteric Softgel Capsules Market was valued at USD 0.420 B in 2024 and is projected to reach approximately USD 0.515 B in 2025. The market is further expected to expand to nearly USD 0.920 B by 2034, registering a compound annual growth rate (CAGR) of about 8.1% during the forecast period from 2026 to 2034. Growth in the market is driven by the increasing demand for targeted drug delivery systems and improved oral dosage formulations in the pharmaceutical and nutraceutical industries. Enteric softgel capsules help protect active ingredients from stomach acid and ensure release in the intestine, improving drug stability, absorption efficiency, and patient compliance.

The India Enteric Softgel Capsules Market was valued at USD 0.452 B in 2024 and is projected to reach approximately USD 0.510 B in 2025. The market is further expected to expand to nearly USD 0.740 B by 2034, registering a compound annual growth rate (CAGR) of about 7.5% during the forecast period from 2026 to 2034. Growth in the market is driven by the increasing demand for targeted drug delivery systems and improved oral dosage formulations in the pharmaceutical and nutraceutical industries. Enteric softgel capsules help protect active ingredients from stomach acid and ensure release in the intestine, improving drug stability, absorption efficiency, and patient compliance.